MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet.
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD.
BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023 MADRID and BOSTON, May 09, 2023 . | May 9, 2023
17.02.2023 - Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) - Oryzon Genomics, S.A. (ISIN .
BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer Epigenetics Institute Symposium: From Genes to Chromatin. | February 6, 2023